Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPYD | Q12882 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HBB | P68871 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22659843 | 0.98 | DPYD (0.45) | DPYDGAAATAD2ALDH1A1LMNA | |
| SCHEMBL28633880 | 0.90 | GAA (0.44) | DPYDGAAMAPT | |
| SCHEMBL2320491 | 0.83 | ALDH1A1 (0.48) | DPYDGAAATAD2ALDH1A1LMNA | |
| SCHEMBL5800398 | 0.81 | — | — | |
| SCHEMBL4353311 | 0.81 | DPYD (0.50) | DPYDGAAATAD2ALDH1A1LMNA | |
| SCHEMBL7599681 | 0.79 | ALDH1A1 (0.45) | DPYDGAAATAD2ALDH1A1LMNA | |
| SCHEMBL161148 | 0.79 | ATAD2 (0.54) | DPYDGAAATAD2ALDH1A1LMNA | |
| SCHEMBL18640304 | 0.78 | KMT2A (0.50) | GAAALDH1A1MAPT | |
| SCHEMBL31326250 | 0.78 | MPO (0.31) | — | |
| SCHEMBL2584919 | 0.77 | LMNA (0.52) | DPYDGAAATAD2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 548 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106525546-B | Analysis method for modifying foam plastic enriched gold by using improved 5-aminomethyl uracil | 中国科学院地质与地球物理研究所 | 2020-01-03 | — | — | CN | claimed |
| US-8802645-B2 | Molecule for treating an inflammatory disorder | PROSENSA TECHNOLOGIES B.V. (NL) | 2014-08-12 | — | — | US | claimed |
| EP-0898575-B1 | A COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | KOESTER HUBERT DR (US) | 2004-12-29 | — | — | EP | claimed |
| US-20030194741-A1 | COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | CAPROTEC BIOANALYTICS GMBH (DE) | 2003-10-16 | — | — | US | claimed |
| US-20030054410-A1 | Combinatorial protecting group strategy for multifunctional molecules | CAPROTEC BIOANALYTICS GMBH (DE) | 2003-03-20 | — | — | US | claimed |
| EP-0898575-A2 | A COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | KÖSTER, Hubert (US) | 1999-03-03 | — | — | EP | claimed |
| WO-1997041139-A2 | A COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | KOESTER HUBERT (US) | 1997-11-06 | — | — | WO | claimed |
| US-20260146249-A1 | ANTISENSE OLIGONUCLEOTIDES FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH AN ABNORMAL PROCESSING OF APP | VICO THERAPEUTICS B.V. (NL) | 2026-05-28 | — | — | US | disclosed |
| WO-2026099473-A1 | OLIGONUCLEOTIDES WITH NEW INTERNUCLEOSIDE LINKAGE | VICO THERAPEUTICS B.V. (NL) | 2026-05-15 | — | — | WO | disclosed |
| EP-4728071-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASE | ProQR Therapeutics II B.V. (NL) | 2026-04-22 | — | — | EP | disclosed |
| EP-4713459-A2 | ANTI-VISTA ANTIBODY RNA OR NUCLEIC ACID CONJUGATES (ARCS OR ANCS), COMPOSITIONS CONTAINING, AND THERAPEUTIC USE THEREOF | LIFORDI IMMUNOTHERAPEUTICS, INC. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4702143-A2 | COMPOSITIONS AND METHODS FOR TREATING STXBP1 DISORDERS | BioMarin Pharmaceutical Inc. (US) | 2026-03-04 | — | — | EP | disclosed |
| EP-4702144-A1 | ANTISENSE OLIGOMERS FOR TREATMENT OF CHRONIC KIDNEY DISEASE | Sarepta Therapeutics, Inc. (US) | 2026-03-04 | — | — | EP | disclosed |
| US-7101883-B2 | Uracil derivatives as inhibitors of TNF-α converting enzyme (TACE) and matrix metalloproteinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-05 | — | — | US | disclosed |
| US-20030229081-A1 | Uracil derivatives as inhibitors of TNF-alpha converting enzyme (TACE) and matrix metalloproteinases | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-11 | — | — | US | disclosed |
| WO-2003079986-A2 | URACIL DERIVATIVES AS INHIBITORS OF TNF-ALPHA CONVERTING ENZYME (TACE) AND MATRIX METALLOPROTEINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-10-02 | — | — | WO | disclosed |
| WO-2003079986-A2 | URACIL DERIVATIVES AS INHIBITORS OF TNF-ALPHA CONVERTING ENZYME (TACE) AND MATRIX METALLOPROTEINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-10-02 | — | — | WO | disclosed |
| EP-1047705-A2 | NUCLEOBASE OLIGOMERS | THE PERKIN-ELMER CORPORATION (US) | 2000-11-02 | — | — | EP | disclosed |
| US-6054568-A | Nucleobase oligomers | THE PERKIN-ELMER CORPORATION (US) | 2000-04-25 | — | — | US | disclosed |
| WO-1999036429-A2 | NUCLEOBASE OLIGOMERS | THE PERKIN-ELMER CORPORATION (US) | 1999-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229081-A1 | Uracil derivatives as inhibitors of TNF-alpha converting enzyme (TACE) and matrix metalloproteinases | UNG, IDUA, TNF | DPYD 32/4885GAA 33/4885ATAD2 2198/4885 |
| US-20030194741-A1 | COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | ADAR, RNMT, ATIC | DPYD 519/4885GAA 3190/4885ATAD2 2080/4885 |
| US-20030054410-A1 | Combinatorial protecting group strategy for multifunctional molecules | ADAR, RNMT, RRM1 | DPYD 362/4885GAA 2513/4885ATAD2 1865/4885 |
| US-20260146249-A1 | ANTISENSE OLIGONUCLEOTIDES FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH AN ABNORMAL PROCESSING OF APP | APP, PSEN2, PSEN1 | DPYD 2591/4885GAA 220/4885ATAD2 1397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.